Crafting Docetaxel-Loaded Albumin Nanoparticles Through a Novel Thermal-Driven Self-Assembly/Microfluidic Combination Technology: Formulation, Process Optimization, Stability, and Bioavailability
Juan Du,Li-Li Shi,Wei-Wei Jiang,Xue-Ai Liu,Xin-Hong Wu,Xiang-Xiang Huang,Ming-Wei Huo,Ling-Zhi Shi,Jingjian Dong,Xiaohong Jiang,Renyu Huang,Qing-Ri Cao,Wenzhou Zhang
DOI: https://doi.org/10.2147/ijn.s457482
IF: 7.033
2024-06-01
International Journal of Nanomedicine
Abstract:Juan Du, 1, &ast Li-Li Shi, 2, &ast Wei-Wei Jiang, 3 Xue-Ai Liu, 3 Xin-Hong Wu, 3 Xiang-Xiang Huang, 3 Ming-Wei Huo, 3 Ling-Zhi Shi, 3 Jingjian Dong, 2 Xiaohong Jiang, 2 Renyu Huang, 4 Qing-Ri Cao, 3 Wenzhou Zhang 1 1 Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People's Republic of China; 2 College of Medicine, Jiaxing University, Jiaxing, People's Republic of China; 3 College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, People's Republic of China; 4 College of Social Science, Soochow University, Institute of Culture and Tourism Development, Soochow University, Suzhou, 215123, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wenzhou Zhang, Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People's Republic of China, Email Qing-Ri Cao, College of Pharmaceutical Sciences, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Jiangsu, 215123, People's Republic of China, Email Background: The commercial docetaxel (DTX) formulation causes severe side effects due to polysorbate 80 and ethanol. Novel surfactant-free nanoparticle (NP) systems are needed to improve bioavailability and reduce side effects. However, controlling the particle size and stability of NPs and improving the batch-to-batch variation are the major challenges. Methods: DTX-loaded bovine serum albumin nanoparticles (DTX-BSA-NPs) were prepared by a novel thermal-driven self-assembly/microfluidic technology. Single-factor analysis and orthogonal test were conducted to obtain the optimal formulation of DTX-BSA-NPs in terms of particle size, encapsulation efficiency (EE), and drug loading (DL). The effects of oil/water flow rate and pump pressure on the particle size, EE, and DL were investigated to optimize the preparation process of DTX-BSA-NPs. The drug release, physicochemical properties, stability, and pharmacokinetics of NPs were evaluated. Results: The optimized DTX-BSA-NPs were uniform, with a particle size of 118.30 nm, EE of 89.04%, and DL of 8.27%. They showed a sustained release of 70% over 96 hours and an increased stability. There were some interactions between the drug and excipients in DTX-BSA-NPs. The half-life, mean residence time, and area under the curve (AUC) of DTX-BSA-NPs increased, but plasma clearance decreased when compared with DTX. Conclusion: The thermal-driven self-assembly/microfluidic combination method effectively produces BSA-based NPs that improve the bioavailability and stability of DTX, offering a promising alternative to traditional formulations. Keywords: DTX-BSA nanoparticles, thermal-driven self-assembly, microfluidic technology, in-vitro release, pharmacokinetics Graphical Docetaxel (DTX) is a first-generation taxane drug that shows good efficacy in the treatment of advanced breast cancer, ovarian cancer, and non-small cell lung cancer. 1–3 A commercially available formulation contains nonionic surfactant polysorbate 80 and ethanol as co-solvent to overcome the challenge posed by the limited solubility of DTX. However, this formulation has been found to be associated with notable adverse effects, including cumulative hypersensitivity reactions, fluid retention, nausea, and peripheral neuropathy. 4 Therefore, novel efficient and surfactant-free alternative formulations for DTX must be developed. Nanoparticle (NP) drug delivery systems, with advantages such as improvement of drug solubility, passive targeting to tumor, and prolonged circulation time, have risen as a hot topic of research. 5–8 Researchers have developed various dosage forms, including polymeric micelles, liposomes, solid lipid NPs, and biomimetic NPs, for encapsulating DTX to enhance its efficient delivery to tumor tissues. 9–11 Among them, albumin attracts increasing attention and has become an effective drug delivery platform owing to its excellent biocompatibility, nontoxicity, non-immunogenic properties, and biodegradability. 12–14 Recent studies have shown that albumin has the ability to target tumor tissue by binding to the highly expressed albumin receptor gp60 and cysteine-rich acidic secretory protein (SPARC) in tumor tissue. 15,16 Albumin-bound paclitaxel (Abraxane) was prepared by NP albumin bound (Nab) technology, a patented novel nanotechnology developed by Abraxis BioScience (CA, USA), and approved by the FDA in 2005 for the treatme -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology